Ake­bia adds $50M deal with Vi­for for ex­clu­sive US dis­tri­b­u­tion deal for vadadu­s­tat

Ake­bia keeps stack­ing up the mon­ey deals for its close­ly-watched ane­mia drug.

In the lat­est deal an­nounced af­ter the mar­ket closed Mon­day, Vi­for Phar­ma said it is buy­ing a $50 mil­lion stake in Ake­bia $AK­BA in ex­change for an ex­clu­sive US dis­tri­b­u­tion deal for their late-stage ane­mia drug vadadu­s­tat. Vi­for is pay­ing $14 a share in the deal to gain dis­tri­b­u­tion rights to the drug for its Fre­se­nius Med­ical Care dial­y­sis clin­ics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER